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Objective: The aim of this study was to examine serum non-coding RNAs as potential biomarkers for
cartilage damage associated with anterior cruciate ligament (ACL) injury.
Methods: Serum was obtained from 80 patients 1 year after surgery for ACL injury and 60 normal donors
without overt skeletal injury. Total serum RNA was isolated, small non-coding RNAs proﬁled by TaqMan
array MicroRNA (miRNA) analysis and individual small RNA assays performed by quantitative TaqMan
RT-PCR (qPCR). Semi-quantitative magnetic resonance imaging (MRI) analysis was performed using
Whole Organ Magnetic Resonance Knee Score (WORMS) scoring for analysis of cartilage damage.
Results: Initial TaqMan array miRNA proﬁling showed an increased serum concentration of a small
nucleolar RNA (snoRNA), U48, in ﬁve patients with cartilage damage compared with that in ﬁve patients
without cartilage damage and six normal donors. Independent qPCR analysis of snoRNAs in serum from
all patients and normal donors showed a strong association between the serum level of another snoRNA,
U38, and cartilage damage in ACL injury patients and together with snoRNA, U48, clear distinction
between ACL injury patients and normal donors.
Conclusion: SnoRNAs U38 and U48 are signiﬁcantly elevated in the serum of patients developing cartilage
damage at 1 year after ACL injury. Serum levels of U38 have the potential to facilitate early diagnosis of
patients with cartilage damage after ACL injury. This study suggests serum non-coding RNAs may serve
as novel noninvasive biomarkers for the detection and assessment of cartilage damage after ACL injury.
 2012 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
There are currently no effective treatments to prevent osteoar-
thritis (OA) or slow its progression1. Lack of biomarkers able to
identify joint pathology before it becomes apparent on radiographs
or to predict disease progression has been a major impediment
for the development of effective therapies1. Previous efforts
have focused logically on identifying the products of articular
cartilage turnover in serum but have been challenged by many
obstacles including: patient and disease heterogeneity; dilution
of biomarkers by synovial ﬂuid, lymph and blood; dilution of
biomarkers with similar products from other joints and tissues;to: G. Gibson, Henry Ford
d., Detroit, MI 48202, United
hang), myang1@bjc.hfh.edu
mtsinai.on.ca (L.M. White),
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s Research Society International. Pbiomarker degradation; and problems associated with the vari-
ability of antibody based assays and the often complex and varied
shape of target molecules.
MicroRNAs (miRNAs) are small (approximately 22 nucleotide)
RNAs that have received enormous research attention in recent
years as overarching post-transcriptional regulators of gene
expression2. Aberrant expression of miRNAs has been associated
with disease development and the recent discovery of miRNAs in
serum and plasma stimulated interest in their potential as circu-
lating biomarkers3. To date there are more than 100 publications
describing circulating miRNA biomarkers of breast, colon, gastric,
lung, oral, ovarian, pancreatic, prostate, tongue and squamous cell
cancers (see4e6 for reviews); stroke and neurologic disorders7,
diabetes8; heart failure8 and lupus erythematosus9. Serum miRNA
biomarkers offer the advantage that they are stable, relatively
abundant and their small size and consistent structure enables the
application of quantitative multiplex assays using quantitative PCR
(qPCR). miRNAs are members of a much larger family of non-
protein coding RNAs (ncRNAs) that constitute most of the tran-
scribed genome10 (only a small percentage of the human genomeublished by Elsevier Ltd. All rights reserved.
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olar RNAs (snoRNAs)12, piwi-interacting RNA (piRNAs)13, long non-
coding RNAs14 and other classes of as yet poorly deﬁned non-
coding RNAs14. SnoRNAs are a class of small guide RNAs resident
in the nucleolus. There are two classes including C/D box snoRNAs
(SNORDs) and H/ACA box snoRNAs (SNORAs) associated with the
respective methylation and pseudouridylation of ribosomal and
some other RNAs12. PiRNAs are a very large class of small RNAs
present in germ line cells, particularly sperm cells and are believed
to function, at least in part, to silence retrotransposons15. Long non-
coding RNAs are a very large diverse class of RNAs and perform an
expanding and wide variety of functions associated with the
regulation of gene expression16. The presence of ncRNAs other than
miRNA in serum and their potential as biomarkers has received
very little research attention.
The investigation of serum biomarkers in patients after anterior
cruciate ligament (ACL) injury has the advantage that, in contrast to
primary knee OA, the development of early degenerative changes
can be studied because the duration of the disease, calculated as the
time since index injury, is known. The patient population is also
more homogeneous, the onset of pathology is relatively rapid and
the course of progression of joint pathology is expected to be
similar to primary OA17. 20e50% of patients develop OA after ACL
injury18 and approximately 12% of all patients with OA can attri-
bute the disease to prior joint trauma19. In this manuscript we
report the comparison of serum concentrations of miRNAs and
snoRNAs with cartilage damage as measured by detailed magnetic
resonance imaging (MRI) assessment in patients at 1 year after ACL
injury and propose the use of serum snoRNA U38 as a potential
biomarker of early cartilage damage associated with post-ACL
injury OA.
Methods
Clinical samples
Serum was collected from 102 patients at 1 year after ACL
reconstruction as part of the ProKnee.ca study. The study pop-
ulation was drawn from 102 consecutive patients presenting for
ACL injury, conﬁrmed by clinical exam and MRI. All patients were
41 years of age or younger without a previous history of knee
surgery or systemic health problems that would affect knee OA
progression. In all study patients arthroscopic ACL reconstruction
surgery was performed within 3 months of the initial injury. Clin-
ical assessment of knee OA pathologywas conducted at year 1 post-
surgery that includedMR imaging evaluation. All MRI examinations
were performed on a 1.5 T MR imaging system (Sign Excite HD, GE
Healthcare, Waukesha, WI) equipped with high-performance
gradients (amplitude, 40 mT/m, slew rate, 200 T/m/sec) utilizing
a dedicated eight-channel transmit-receive knee coil (Invivo Corp.,
Orlando, FL). Imaging sequences performed included a sagittal fast
spin-echo (FSE) proton density weighted sequence optimized for
evaluation of the menisci, a coronal FSE intermediate weighted
sequence, an axial and sagittal FSE T2 weighted sequence with fat
suppression, and a sagittal 3D SPGR acquisition with fat saturation.
A semi-quantitative evaluation of articular cartilage was made for
the medial and lateral tibial plateaus, femoral condyles, as well as
the trochlear and patellar articular surfaces using the Whole Organ
Magnetic Resonance Knee Score (WORMS)20. The total score for
articular cartilage was obtained by adding the scores for each of the
16 regions of the joint. Serum was also collected from 60 healthy
donors [29 donors were age-matched (within 7 years) with ACL
injury patients and 31 were older donors] presenting at Henry Ford
Health System for annual physical exam without evidence of
skeletal or systemic health problems.The blood samples from all patients were collected and were
allowed to coagulate for 30 min at room temperature and centri-
fuged for 10 min at 1300g. The collected sera were centrifuged
further for another 10 min at 3000g to remove any remaining
cellular component, divided into 500 ml aliquots and stored
immediately at 80C.
Serum RNA isolation
Total RNAwas isolated from serum using the miRNeasy mini kit
(Qiagen, CA, cat.no.217004) with some modiﬁcations. In brief,
400 ml serum was added to 10 volume QIAzol lysis reagent, mixed
thoroughly by vortexing and left to stand at room temperature
for 5 min. 1/5 volume chloroformwas added, shaken vigorously for
30 s, incubated for 5 min at room temperature and centrifuged for
20 min at 12,000g at 4C. The upper aqueous phase was trans-
ferred to a new collection tube, 1.5 volume of 100% ethanol added,
mixed thoroughly and loaded onto an RNeasy spin column on
a vacuum manifold. The column was washed twice with 500 ml
buffer RWT and 500 ml buffer RPE. RNA was eluted by two
sequential 50 ml volumes of RNase-free water. The quality of RNA
was proﬁled using NanoDrop 2000 (Thermo scientiﬁc, USA).
Reverse transcription
A ﬁxed volume of RNA solution was reverse transcribed using
the TaqMan miRNA reverse transcription kit (Invitrogen, USA, Part
No. 4366596) using pooled individual miRNA/snoRNA-speciﬁc
stem-loop RT primers (Applied Biosystems, Foster City, CA). To
increase reverse transcription efﬁciency, a pulsed RT reaction, using
the Eppendorfmastercycler (Eppendorf, NY) employing 40 cycles at
16C for 2 min, 42C for 1 min and 50C for 1 s, followed by reverse
transcriptase inactivation at 85C for 5 min was employed. cDNA
was used immediately for PCR or stored at 80C.
MiRNA expression in serum samples from healthy donors and
ACL injury patients was proﬁled using Low Density TaqMan miRNA
arrays on a 7900 HT real time PCR System. TaqMan Human miRNA
array A and array B (Megaplex RT human pool A and pool B) were
used following the manufacture’s recommended protocol. The
serum RNA was reverse transcribed using the TaqMan miRNA
reverse transcription kit and the TaqMan miRNA multiplex RT
assays. Each Megaplex RT reaction was followed by one pre-
ampliﬁcation reaction per array with Megaplex PreAmp primers
and TaqMan PreAmp master mix. cDNA from multiplex RT reac-
tions was diluted with water and each diluted product combined
with TaqMan 2 universal PCR master mix (No AmpErase UNG).
100 ml of the PCR reaction mix was dispensed into each port of the
TaqMan miRNA array and qPCR was performed on an Applied
Biosystems 7900 HT thermocycler at the manufacturer’s recom-
mended cycling conditions. SDS relative Quantiﬁcation Software
version v2.2 was used for data analysis. MiRNA expression was
adjusted for small differences in extraction efﬁciency using global
normalization. Applied Biosystems (Life Technologies, CA) instru-
ments, software and reagents were used throughout.
TaqMan qPCR assay
The serum RNA concentration is usually very low, which limits
the number of small RNAs that can be measured by qPCR. Pre-
ampliﬁcation enables the RNA/cDNA assayed to be expanded to
enhance the number RNAs able to be analyzed and may enhance
sensitivity of qPCR. The pre-ampliﬁcation was performed in
a small-scale (10 ml) reaction comprised 5 ml 2 TaqMan PreAm
master mix (Applied Biosystems, CA), 2.5 ml pooled individual
TaqMan miRNA assay mix (0.2), 1.25 ml of undiluted RT product
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Fig. 1. Comparison of miRNA concentration in serum from ACL injury patients with
and without cartilage damage and serum from normal donors. (A) Comparison of
miRNA levels in serum from ACL injury patients developing cartilage damage (OA,
WORMS score 13e35) and patients without evidence of cartilage damage (Control,
WORMS score 0). (B) Comparison of miRNA levels in serum from ACL injury patients
with cartilage damage and normal donors. miRNAs were analyzed by ABI TaqMan
array after RNA isolation from 0.4 ml serum. Each point represents the average and SD
of the Ct of a miRNA from ﬁve patients or six normal donors. Points below the normal
distribution, such as that shown in red, have higher levels in serum from patients
developing cartilage damage. The ncRNA shown in red is snoRNA U48.
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Eppendorf mastercycler, cycling at 95C for 10 min, followed by
14 cycles of 95C for 15 s and 60C for 4 min, followed by 99C for
10 min. The pre-ampliﬁcation PCR product was diluted threefold,
mixed and centrifuged brieﬂy.
qPCR was performed in duplicate using the TaqMan qPCR assay,
each PCR application reaction was performed in a ﬁnal volume of
20 ml containing 1.2 ml of cDNA, 10 ml TaqMan 2 universal PCR
Master mix, 1 ml miRNA/snoRNA-speciﬁc primer/probe mix, and
7.8 ml of pure water. RT-PCR was carried out on an Applied Bio-
systems 7500 thermocycler, using the following condition: 95C for
10 min, followed by 40 cycles of 95C for 15 s and 60C for 1 min.
Raw data were analyzed with SDS relative Quantiﬁcation Software
version 2.2.3 (Applied Biosystems, Inc). The data were normalized
to U6 small nuclear RNA using the median procedure21.
Synthetic single stranded RNA oligonucleotides corresponding
to the sequence of U38 and U48 were purchased from Invitrogen
(Life Technologies, NY). A series of dilutions of synthetic RNA
oligonucleotides were made to generate real time qPCR cycle
threshold (Ct) standard curves. The lower limit for detection was
designated as the Ct where the linear logarithmic relation with
concentration was no longer maintained.
Stability at room temperature
A growing number of studies have shown that serum miRNAs
are stable to freeze thawing and can be stored for many weeks
at 80C and at least 24 h at room temperature without loss3.
400 ml aliquots of the serum from several individuals was processed
immediately and allowed to incubate for extended times (0 h, 1 h,
2 h 4 h and 8 h) at room temperature (25C) in 2 ml RNase/DNase-
free tubes or subjected to four cycles of freeze thawing and
immediately processed for RNA isolation. SnoRNAs were analyzed
by TaqMan qPCR as described (Supplemental Fig. 2).
Only one study to our knowledge has described snoRNAs in
serum or plasma22. Our studies of serum snoRNAs conﬁrm their
description of snoRNA stability. We did not ﬁnd any signiﬁcant
change in serum content of U6, hY3, U38 or U48 with storage for up
to 8 h at room temperature; freeze thawing for up to four cycles or
prolonged storage (6 months) at 80C. The stability of the snoR-
NAs was similar to that of miR-16 and miR-197 analyzed in parallel
(data not shown).
Statistical analysis
Associations between snoRNA measures and WORMS cartilage
score or age were made by Spearman’s rank correlations. SnoRNA
associations with groups deﬁned by WORMS cartilage score or
donor group (normal vs ACL/OA) were assessed by Wilcoxon rank
sum tests. The ability of snoRNA copy number to discriminate
patients with low versus high relative WORMS scores was assessed
by receive operator characteristic (ROC) curve construction.
Results
Due to the very low level of serum RNA, we ﬁrst investigated the
speciﬁcity and sensitivity of the available PCR-based assays for
detecting miRNAs. Two main methods have been available. One is
based on miRNAs polyadenylated by poly (A) polymerase and
reverse transcribed into cDNA and the other based on stem-loop
reverse transcription primers which generate miRNA-speciﬁc
cDNA templates. In our hands the stem-loop strategy has proven
to be robust, highly sensitive and speciﬁc for detecting miRNAs.
Most importantly, stem-loop based qPCR is based on a newly
created template by each individual stem-loop RT primer and thisoffers unmatched speciﬁcity and robust performance for detecting
low abundant serum small RNAs, avoiding possible false-positive
signals derived from rare contaminated genomic DNA or reagent
carry-over.
To investigate the potential of miRNAs as serum biomarkers of
OA, array analysis of serum from ﬁve patients developing cartilage
pathology as determined by detailed MRI analysis (average total
WORMS scores 23 range 13e35) was compared with serum from
ﬁve patients without evidence of cartilage damage at 1 year after
ACL injury. Serum miRNAs were also analyzed from six healthy
donors without overt skeletal pathology. Approximately 300
miRNAs could be detected in human serum and approximately
150 miRNAs were present in concentrations sufﬁcient to enable
reliable measurement, using the TaqMan array.
The serum levels of miRNAs were very similar in patients with
and without cartilage pathology or with normal donors (Fig. 1).
Those few miRNAs showing different serum levels in patients with
and without cartilage pathology were further analyzed using
independent TaqMan qPCR assays in serum samples from these and
additional patients. The RNA that showed the largest difference in
serum levels between patient groups was a non-coding RNA (U48)
used as control in the miRNA array. It was also the only RNAwhose
levels remained signiﬁcantly different between patients with and
without cartilage damage or between patients with cartilage
damage and healthy donors on further analysis. To determine if
other snoRNAs could be detected in serum and if their
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additional 12 snoRNAswere analyzed. Three snoRNAs in addition to
U48 had serum levels consistently above the limits of detection.
U24, U48, U49 and U38 all showed a signiﬁcant increase in serum
concentration in ACL surgery patients with cartilage damage
compared with our healthy donors. The serum levels of these
snoRNAs also showed a tendency to higher concentration in
patients with cartilage damage compared to those without carti-
lage damage; however, the increase was signiﬁcant for U38 only
(Supplemental Fig. 1). The analysis of U24 and U49 was limited by
low serum levels, close to the limits of detection and thus not
examined further. Analysis of serum levels of U48 and U38 was
highly reproducible. Analysis of eleven aliquots of a mixture of
serum from several patients generated an average Ct for U48 and
U38 of 18.8þ 0.9 [4.7% standard deviation (SD)] and 22.6þ 0.9
(3.8% SD) respectively or copy number of 42,000þ 27,000 (64%
SD) and 3600þ 1500 (42% SD), respectively. Normalization with
U6 reduced the SD to 2.5 and 2.5% for Ct and 32 and 34% for copy
number for U48 and U38 respectively.
Analysis of serum U38 and U48 was expanded to 80 patients at
1 year after ACL surgery and 60 healthy donors, 29 of whom that
were age-matched with surgery patients. RNA copy number was
determined using standardization with a serial dilution of U38 and
U48 RNA oligonucleotides. Patient cartilage pathology was strati-
ﬁed from WORMS scores determined from detailed MRI analysis.
U38 levels were below the limits of detection in 28 of the 29 serum
samples from normal healthy donors and not signiﬁcantly different
from ACL injury patients without cartilage damage (WORMS score
0) or with minor cartilage damage (WORMS score of 1e3). Patients
with greater cartilage damage (WORMS score of 4) had signiﬁ-
cantly higher U38 serum levels than either normal donors orU48
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Fig. 2. The association between serum snoRNA U48 and U38 levels and cartilage pathology.
was determined by RT-PCR after reverse transcription. Cartilage damage was determined by
WORMS score (rs ¼ 0.13, P ¼ 0.27 for U48 and rs ¼ 0.38, P ¼ 0.001 for U38). (B) The data wer
injury patients (0, 1e3, 4e8 and >8). Copy number in age-matched normal donors (normal
age-matched control or patients with WORMS scores of 0 or 1e3 and patients with WO
comparisons to ACL groups had P < 0.05. None of the ACL group to group differences werepatients with minor cartilage damage (WORMS scores below 4)
(P < 0.001). U48 showed similar trends to U38, although levels in
ACL injury patients were not signiﬁcantly correlated with level of
cartilage damage (rs ¼ 0.02, P ¼ 0.84). Serum levels of U48 in
patients with cartilage damage (WORMS score 4) were signiﬁ-
cantly different to that in healthy donors (Fig. 2).
A WORMS score of 3 has been reported in individuals without
symptomatic joint pathology23 and considered here to provide
a cutpoint between patients with and without clear articular
cartilage damage. Consequently ROC analysis was performed
comparing ACL injury patients with WORMS scores up to and
including 3 (49 patients) versus those above 3 (30 patients). ROC
curves of U38 reﬂected strong separation between these patients
with area under the curve (AUC) of 0.743 (95% conﬁdence interval
0.621e0.865) (Fig. 3).
Serum levels of U48 in healthy donors or patients at 1 year after
surgery for ACL injury showed no signiﬁcant change with age
between ages 20e75 years (rs ¼ 0.17, P ¼ 0.20) or 18e41
(rs ¼ 0.09, P ¼ 0.51), years respectively (Fig. 4). The relationship
between donor age and serum levels of U38 could not be analyzed
for healthy donors because very few serum samples contained
detectable U38. There was also no relationship between donor age
and serum U38 levels for patients at 1 year after surgery for ACL
injury (rs ¼ 0.07, P ¼ 0.59).
Discussion
Serum or urine biomarkers of joint degeneration associated
with OA have the potential to improve treatment options by
providing early diagnosis and facilitating much needed develop-
ment of new drugs and therapeutic approaches24,25. Our studies ofU38
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Fig. 3. ROC Plot. The data shown in Fig. 2 were used to draw a ROC plot comparing;
U38 serum levels in ACL injury patients with no or very mild cartilage damage
(WORMS score 3) and patients with greater cartilage damage (WORMS score 4).
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by published studies describing the characterization of serum and
plasma miRNAs as biomarkers of several diseases; observations
that have grown out of a huge increase in our knowledge of miRNAs
and their functions in the last decade. Changes in serum snoRNAs
but not miRNAs were associated with cartilage damage in post-ACL
injury patients. Previous analyses have shown that miRNAs can be
detected in plasma and synovial ﬂuid of patients with rheumatoid
arthritis (RA) and primary OA. Plasma levels were generally similar
between RA patients, OA patients and healthy controls except miR-
132 that was shown to have signiﬁcantly lower levels in the RA and
OA patients compared with healthy controls26. In our array studies
the levels of miR-132 were similar and close to the limits of
detection in serum from patients with or without cartilage damage
at 1 year after ACL injury and in our healthy donors. We did not
analyze miRNAs or snoRNAs in synovial ﬂuid from any donors or in
serum from patients with primary OA. SnoRNAs (and other
ncRNAs), like miRNAs, are emerging as important regulators of cell
function and disease development. Mutations in snoRNAs (SNORD
115 and 116) have been shown to cause a neuro-developmental
disorder, Prada-Willi syndrome27; snoRNA U50 has been shown
to be a tumor suppressor gene down regulated in breast and
prostate cancer28 and SNORA 42 has been shown to be associated
with non-small-cell lung cancer29. Other studies have shown that
loss of three snoRNAs, U32a, U33 and U35, is sufﬁcient to confer
resistance to cell death induced by oxidative stress in vitro and
in vivo30. Furthermore, current studies, primarily conducted in
yeast, suggest that snoRNAs ﬁne-tune the ribosome to accommo-
date changing requirements for protein production during devel-
opment, normal function and potentially diseases such as cancer31.age
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Fig. 4. Age association of serum concentration of U48. The serum concentration of U48
(copy #) from ACL injury patients (open circles) or normal donors (black diamonds) is
plotted against the age of the donor.It is becoming increasingly evident that the regulation of ribosome
function and activity (and by analogy snoRNA expression) plays
a pivotal role in regulating the function of high protein producing
cells such as, chondrocytes and other connective tissue cells, and is
reﬂected in the phenotypes of ribosomophathies32. Emerging data
also indicate that the nucleolus responds acutely to cell stress
which can stimulate p53 expression, apoptosis33,34 and autophagy
(piecemeal microautophagy or nucleophagy)35.
The detection of snoRNAs in serumwas surprising since they are
normally resident in the nucleolar subcompartment of the nucleus
and except for one publication22 have not been described in the
circulation. Consistent with the previous report our studies have
shown that snoRNAs are very stable in serum. Our preliminary
studies (data not shown) suggest that, like the bulk of miRNAs,
serum snoRNAs are not present in microvesicles or exosomes but
are present as stable, unidentiﬁed protein complexes. Several
mechanisms for the release of miRNAs from cells and into the
circulation have been proposed. These include exocytosis in
microvesicles or exosomes36, release as protein complexes37,38 or
the consequence of cell death39. Cell to cell transfer of functional
miRNAs has been demonstrated in culture and has been proposed
for circulating miRNAs6. The mechanism of release of snoRNAs has
not been reported, however; apoptosis and modulation of the
normal, autophagic process can result in the release of cell
components including those of the nucleus and nucleolar
compartment40.
The development of biomarkers for post-traumatic OA has the
distinct advantage over studies of primary OA that the time of onset
of the disease (injury to the ACL in the present studies) and thus
duration of the disease is known. In this study detailed clinical,
functional and MRI assessment of the entire knee joint allowed
stratiﬁcation of ACL injured patients and early diagnosis of subtle
cartilage damage consistent with the early OA. The association
between the cartilage damage analyzed and the serum levels of
U38 suggests analysis of U38 in serum can provide a biomarker of
early events in joint degeneration. The elevated levels of U38 and
U48 in serum of ACL injury patients without visible cartilage
damage compared with normal donors suggests serum levels of
these snoRNAs might be associated with the initial injury.
However; distinct differences in serum levels of U38 between
patients with and without cartilage damage after ACL injury
suggests the serum levels of U38 are associated with early events in
joint degeneration rather than the consequence of the initial injury.
Also the absence of changes in serum U38 (or U48) with age in our
normal donors suggests that serum U38 is not associated with
normal aging or age-related cartilage degeneration, which takes
placemore slowly. The highest levels of U38 in serumwere found in
patients with relatively low WORMS scores (5e10) suggesting
release of U38 might be associated with events earlier in joint
degeneration than are readily detected by MRI analysis. Whether
the serum levels of U38 and U48 are prognostic of further cartilage
damage will be determined when serum and clinical analysis from
follow-up studies at years 2e5 after ACL injury become available.
Our analysis included only a very small proportion of the esti-
mated approximately 500 snoRNAs expressed in the human
genome41. Whether other snoRNA biomarkers of cartilage damage
are found will require sensitive array analysis or sequencing of
serum RNAs. The link between serum U38 and cartilage damage
remains to be determined. At present the source of the serum
snoRNAs is unknown; however, it seems unlikely that these
snoRNAs come from damaged articular cartilage. Although snoR-
NAs, like miRNAs, are stable in serum and are not as susceptible as
proteins or carbohydrates to enzyme digestion, they would be ex-
pected to be similarly diluted by synovial ﬂuid and blood such that
snoRNAs released from a small number of damaged chondrocytes
L. Zhang et al. / Osteoarthritis and Cartilage 20 (2012) 1631e16371636would be undetectable by the time they reached the peripheral
circulation. RNA sequencing studies have shown substantial tissue
speciﬁcity in snoRNA expression. U38 concentrations have been
shown to be 20e100 fold greater than U48 in all tissues studied
(heart, liver, kidney, skeletal muscle, brain, adipose, colon, ovary,
testes and spleen, connective tissues were not analyzed)42 in
marked contrast to the analysis of their relative serum levels in the
present studies. This might suggest that U38 and U48 came from
tissues not analyzed previously or that speciﬁc snoRNAs are
secreted under certain conditions. SnoRNAs have the advantage
that serum levels are largely unaffected by hemolysis (a problem in
serum miRNA analysis) due to the absence of the nucleolus and
nucleus in erythrocytes.
In conclusion our studies have shown that the levels of snoRNAs
can be analyzed in serum and that the level of U38 and U48 is
elevated at 1 year after ACL injury. Furthermore the serum levels of
U38 are substantially elevated in those patients who develop
cartilage damage after ACL injury suggesting snoRNA U38 is
a serum biomarker for early cartilage damage.Author contributions
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